A new trial highlights that the timing of chemoradiation and immunotherapy is crucial when treating limited-stage small cell ...

"Tumor behavior upon recurrence is often more aggressive, and patients may quickly exhaust safe and effective options for ...

After 19 weeks on daily oral HU6 treatment, people shed on average 2.9 kg (~6.3 lb) or 2.7% of their starting body weight ...

Bill Gates visiting TerraPower Isotopes, the subsidiary of the nuclear power company TerraPower that he helped found. Gates ...

Adding immunotherapy to chemoradiation therapy (CRT) for limited-stage small cell lung cancer (SCLC) failed to improve ...

Jefferies analyst Peter Welford maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £114.00.

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced ...

AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE ® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously ...

The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...

Wednesday announced a clinical trial collaboration agreement with AstraZeneca (AZN) to evaluate casdatifan in combination with volrustomig for the treatment of clear cell renal cell carcinoma or ccRCC ...

Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...